Business Context and Reporting Period
This Form 8-K, dated February 3, 2026, is filed by Churchill Capital Corp X (Churchill X) regarding its business combination with ColdQuanta, Inc. (d/b/a Infleqtion). The filing announces the intent to transfer the listing of Churchill X's Class A ordinary shares and warrants from the Nasdaq Stock Market to the New York Stock Exchange (NYSE) upon completion of the transaction. Churchill X will also transfer its registration from the Cayman Islands to the State of Delaware.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for Infleqtion or Churchill X. The filing text does not provide a clear value for any financial metrics.
Material Changes and Transaction Details
- Listing Transfer: Churchill X notified Nasdaq of its intent to transfer listing to the NYSE following the business combination.
- Share Conversion: Each Class A Ordinary Share will convert one-for-one into common stock of the combined company. Each outstanding warrant will convert one-for-one into warrants for the common stock.
- Unit Separation: Prior to closing, Units will separate into one Class A Ordinary Share and one-quarter of one warrant. Units will cease trading on Nasdaq.
- Trading Timeline:
- Nasdaq trading for Class A shares, warrants, and units is expected to end at market close on February 13, 2026.
- NYSE trading for the new Common Stock and Warrants is expected to begin at market open on February 17, 2026.
- New Tickers: Post-combination, the Common Stock will trade under the symbol "INFQ" and Warrants under "INFQ WS".
Guidance, Outlook, and Risks
The filing includes extensive forward-looking statements regarding market opportunity, commercialization timelines, and the benefits of the transaction. Management cautions that actual results may differ materially due to various risks, including:
- Significant technical challenges and the risk of failing to achieve commercialization or market acceptance for emerging quantum technologies.
- Historical net losses and limited operating history of Infleqtion.
- Concentration of revenue in contracts with government or state-funded entities.
- The potential need for additional future financing.
- Risks associated with shareholder redemptions leaving the combined company with insufficient cash.
- Regulatory approval delays or denials.
Shareholders are advised to review the definitive proxy statement/prospectus filed on Form S-4 (effective January 23, 2026) for detailed information.
Investor Verification Checklist
- Verify the final trading dates on Nasdaq (Feb 13, 2026) and NYSE (Feb 17, 2026) for the specific securities held.
- Confirm the new ticker symbols "INFQ" and "INFQ WS" for post-combination trading.
- Review the definitive proxy statement/prospectus (Form S-4) for details on the business combination terms and voting procedures.
- Assess the risk of shareholder redemptions impacting the combined company's liquidity.
- Monitor the status of regulatory approvals required to close the transaction.